Browse News
Filter News
Found 167 articles
-
Key Capital Advises Urgent Global Need For COVID-19 Oral Pill Therapeutic Vaccine
1/6/2021
KEY CAPITAL CORPORATION advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis.
-
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
-
Vaxart Hosting Key Opinion Leader Panel Call for Investors - Nov 16, 2020
11/16/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that it will host a Key Opinion Leader panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020 at 12pm Eastern Time.
-
Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
11/16/2020
Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below: Jefferies 2020 Virtual London Healthcare Conference, November 17-19, 2020 Management will de
-
Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a significant immune response.
-
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
11/12/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter of 2020 and provided a corporate update, including updates on its oral COVID-19 vaccine pre-clinical studies and clinical trials.
-
Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 VaccineRobust Immune Response and Significantly Reduce Viral Load
11/12/2020
Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its Hamster Challenge Study
-
Clinical Catch-Up: October 12-16
10/19/2020
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look. -
Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 VaccineVaccinated Hamsters Show Protection from COVID-19 based on Prespecified Indicators of Clinical Outcomes
10/14/2020
Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today the topline results from its Hamster Challenge Study.
-
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
10/13/2020
Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are advancing VXA-CoV2-
-
Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
10/7/2020
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has expanded an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine for COVID-19 and other vaccine candidates.
-
Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates
10/7/2020
Centaur Biopharmaceutical Services Inc. (Centaur), a wholly-owned subsidiary of Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), today announced an expanded agreement between KindredBio and Vaxart, Inc. (Nasdaq: VXRT) under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and other vaccine candidates
-
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. -
IMV CEO to Participate at the Vaccines Panel of the Sachs Associates 20th Annual Biotech in Europe Forum
9/16/2020
IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, announced that company’s Chief Executive Officer, Frederic Ors will participate at the Vaccines Panel of the 20th Annual Biotech in Europe Forum held on September 21-24, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
-
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
9/14/2020
Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
-
Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies
9/8/2020
Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”
-
Vaxart, Inc. to Participate in September Virtual Investor Conferences
9/3/2020
- H.C. Wainwright: 22 nd Annual Global Investment Conference - September 14 th – 16 th - Sachs Associates: 20 th Annual Biotech in Europe Forum - September 21 st – 24 th - SVB Leerink: CybeRx Series: Vaccine Forum - September 23 rd & – 24 th